CXCR4 inhibition in tumor microenvironment facilitates anti-PD-1 immunotherapy in sorafenib-treated HCC in mice

Sorafenib—a broad tyrosine kinase inhibitor—is the only approved systemic therapy for advanced hepatocellular carcinoma (HCC), but provides limited survival benefits. Recently, immunotherapy has emerged as a promising treatment strategy, but its role remains unclear in HCCs, which are associated wit...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Hepatology
Main Authors: Chen, Yunching, Ramjiawan, Rakesh R., Reiberger, Thomas, Ng, Mei R., Hato, Tai, Huang, Yuhui, Ochiai, Hiroki, Kitahara, Shuji, Unan, Elizabeth C., Reddy, Tejaswini P., Fan, Christopher, Huang, Peigen, Bardeesy, Nabeel, Zhu, Andrew X., Jain, Rakesh K., Duda, Dan G.
Format: Artigo
Jezik:Inglês
Izdano: 2015
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4406806/
https://ncbi.nlm.nih.gov/pubmed/25529917
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/hep.27665
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki